|
|
Article: Studying Receptor Function Yielding Targets For Disease.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Science Editor
Bone density is the end result of an interplay between two cell types: bone-forming osteoblasts and bone-chomping osteoclasts.
Over the course of a lifetime (according to U.S. statistics), the osteoclasts appear to win out: The National Osteoporosis Foundation said one in two women and one in four men older than 50 will have an osteoporosis-related fracture in her or his remaining lifetime.
That presents a market opportunity, as well as a public health problem, something that has not escaped the notice of the biotech industry.
Companies working in the space include Salt Lake City-based NPS Pharmaceuticals Inc., which ...